3.3. Secondary Endpoint Measurement
After 24 weeks of treatment, the HbA1c level of the pioglitazone-metformin combined treatment group and the metformin treatment group decreased significantly (pioglitazone-metformin combined treatment: 1.78% (95% CI: 1.53-2.04) and metformin treatment: 1.71% (95% CI: 1.46-1.96)), but there was no significant difference between the two groups (There is no statistically significant reduction in BMI, and waist circumference was observed in the pioglitazone-metformin combined treatment group after 24-week treatment compared to the metformin. Moreover, there was no significant change in the pioglitazone-metformin combined treatment group and the metformin group when compared with the baseline level (